Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1Pulmonary Atelectasis 1Postural Orthostatic Tachycardia Syndrome 1Postoperative Complications 1Pneumonia 1Pancreatic carcinoma, familial 1Pancreatic cancer, adult 1Neoplasms 1Multiple Myeloma 1Mastocytosis 1Lung Cancer Screening 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Bronchopulmonary Disease 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Nivolumab 17Standard of Care 15Carboplatin 15Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Mass Screening × 90 days × Clear all
NCT04663958 2026-04-30

Predictive Value of Ariscat Index In The Development of Pulmonary Complication After Major Abdominal Cancer Surgery

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Completed
410 enrolled

Pulmonary Atelectasis, Neoplasms, Pneumonia, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon âš¡